TargaZyme

TargaZyme

Growth Stage

The Next Frontier of Cancer Medicine

The Next Frontier of Cancer Medicine

Overview

Raised this Round: Raised: $73,867

Total Commitments ($USD)

Platform

StartEngine

Start Date

05/23/2022

Close Date

09/19/2022

Min. Goal
$9,996
Max. Goal
$1,069,997
Min. Investment

$305

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$6.62

Pre-Money Valuation

$196,273,335

Year Founded

2005

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

High

Capital Intensity

High

Location

Carlsbad, California

Business Type

Growth

TargaZyme, with a valuation of $196 million, is raising funds on StartEngine. The company is pioneering the development of cancer medicine that harnesses the power of the patient’s own immune system. The company is in the R&D stage and trying to eliminate chemotherapies, radiation, radical surgery, and other toxic drugs as treatments for cancer. The novel patented medicine of TargaZyme, TZ101, has shown to improve survival rates of cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant. Lynnet Koh founded TargaZyme in November 2005. The current crowdfunding campaign has a minimum target of $9,996.20 and a maximum target of $1,069,997.22. The campaign proceeds will be used to enable the delivery of cancer cures, further development of additional cures, and generate multiple revenue streams.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-2,416,916

$-2,483,254

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$111,900

$19,562

Accounts Receivable

$0

$0

Total Assets

$3,174,319

$3,455,588

Short-Term Debt

$7,524,097

$7,336,075

Long-Term Debt

$441,014

$203,700

Total Liabilities

$7,965,111

$7,539,775

Financials as of: 05/23/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
TargaZyme on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $196,273,335
Price per Share: $6.62

Follow company

Follow TargaZyme on StartEngine 2022

Buy TargaZyme's Deal Report

Warning: according to the close date for this deal, TargaZyme may no longer be accepting investments.

TargaZyme Deal Report

Get KingsCrowd’s comprehensive report on TargaZyme including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether TargaZyme is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the TargaZyme deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge